Game Changer For Cancer Prevention And The Fight To Push Back On Increased Incidences Of Colon Cancer
The FDA recently approved Shield, a blood test by Guardant Health, for screening colorectal cancer in individuals aged 45+ with an "average risk." While not a substitute for colonoscopies, Shield aims to enhance accessibility and insurance coverage, potentially increasing screening rates due to its convenience. The test, with a 10% false positive rate and